Rezultati pretraživanja
  1. 15. sij

    The first collaboration under the agreement involves scaling up and integrating UC Davis’ lentiviral vector process as part of the Orgenesis POCare platform for localized, development and processing of cell and for treating patients.

  2. 29. kol 2017.
  3. 4. pro 2017.

    Though the headlines offer eye-catching numbers for their costs, are durable, potentially curative therapies. They’re often more cost effective when compared to lifelong treatment.

  4. 9. tra 2019.

    For the 2nd time in as many months, researchers have landed a journal cover for their work on the development of for brain & eye disorders. Check out the study in from the Simpson, Wasserman & Goldowitz Labs

  5. 10. kol 2016.

    .@Abeona_Bio licenses for rare skin diseases

  6. 24. velj 2019.

    Roche has entered into a definitive merger agreement with Spark Therapeutics, a pioneering gene therapy company.

  7. 23. stu 2015.

    Why -Cas9 technology could work in CF where haven't.

  8. 23. stu 2016.

    Is the UK poised to become the next global hub 4 cell & ? Discover the action plan:

  9. Spinal injury researchers find a sweet spot for stem cell injections. Congratulations to researchers at !

  10. 8. stu 2017.
  11. 11. ruj 2019.

    The first approved have transformed lives — but current delivery methods are limited. In this blog post, our CEO, , explores a different bio-delivery system that can reach tissues not targeted by vectors. Read more:

  12. Researchers from University of Iowa found a new gene therapy, approval from FDA could open the door for other that could eventually treat more than 225 genetic mutations known to cause .

  13. Dr Isabelle Richard from Généthon will be discussing for limb girdle muscular dystrophies at our information day on 21 April. Don't miss out - book your place today!

  14. Check out our own and @Datamonitor_TI discussing and pricing in !

  15. It’s a great day for patients, genetic medicine and the city of Philadelphia. will help us accelerate the development of more for more patients with new diseases and further expedite ’s vision of a world where no life is limited by genetic disease.

  16. 16. tra 2019.

    John Chiminski, CEO of Catalent talks about the acquisition of Paragon Bioservices, Inc. that focuses on . “We look forward to working with Paragon’s incredibly talented team to deliver lifesaving treatments.” Learn More:

  17. 26. stu 2018.
  18. 24. velj 2019.

    Spark Therapeutics, a pioneering company in the field of gene therapy, entered into an agreement to join the Roche Group as an independent company based in Philadelphia.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.